Qube Research & Technologies (QRT)’s Mineralys Therapeutics MLYS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74M	Sell	249,776 -664,952	-73%	-$18.2M	0.01%	1484
2026 Q1	$24.8M	Buy	914,728 +418,179	+84%	+$12.3M	0.03%	765
2025 Q4	$18M	Buy	496,549 +316,123	+175%	+$12.7M	0.02%	970
2025 Q3	$6.84M	Sell	180,426 -170,687	-49%	-$3.69M	0.01%	1547
2025 Q2	$4.75M	Buy	+351,113	New	+$5.09M	﹤0.01%	1735
2024 Q2	–	Sell	-1,025	Closed	-$13.2K	–	4400
2024 Q1	$13.2K	Buy	1,025 +301	+42%	+$3.72K	﹤0.01%	3763
2023 Q4	$6.23K	Buy	724 +261	+56%	+$2.05K	﹤0.01%	3684
2023 Q3	$4.4K	Buy	+463	New	+$6.04K	﹤0.01%	3471

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MLYS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Mineralys Therapeutics (MLYS) stake by 73% in Q2 2026, selling an estimated $18.2M and leaving 249,776 shares worth $6.74M. The position accounts for 0.01% of the portfolio, ranked #1484.

Qube Research & Technologies (QRT) first reported a position in MLYS in Q3 2023 and has held it in 8 quarters since. The position peaked at $24.8M in Q1 2026. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Qube Research & Technologies (QRT) held 249,776 shares of Mineralys Therapeutics worth $6.74M as of Q2 2026.
Qube Research & Technologies (QRT) sold 664,952 Mineralys Therapeutics shares in Q2 2026, an estimated $18.2M.
Mineralys Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1484 holding.
Qube Research & Technologies (QRT) first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 8 quarters since.
Qube Research & Technologies (QRT)'s Mineralys Therapeutics position peaked at $24.8M in Q1 2026.
225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.